(Q45790670)

16 December 2017

title

Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer (English)

1 reference

16 December 2017

0 references

1 reference

2

Rosenberg SA

1 reference

16 December 2017

Michael T Lotze

series ordinal

1

object named as

Lotze MT

1 reference

16 December 2017

publication date

1 September 1986

1 reference

16 December 2017

published in

Immunobiology

1 reference

16 December 2017

volume

172

1 reference

16 December 2017

issue

3-5

1 reference

16 December 2017

page(s)

420-437

1 reference

16 December 2017

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Identification of T cell lymphoma tumor antigens on human T cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Purification and partial sequence analysis of human T-cell growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980122-X

7 January 2021

10.1016/S0171-2985(86)80122-X

Identifiers

DOI

0 references

1 reference

16 December 2017